Children with chronic phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML
Five hundred and thirty-five patients (median age 12.2 years, range: 8 months - 18 years; N=303 males, N=232 females) diagnosed with chronic myeloid leukaemia (CML) in chronic phase were registered in the International Registry of Childhood CML (www.clinicaltrials.gov NCT01281735). Clinical signs of leukostasis or bleeding were observed in 16.5% and 20% of the patients, respectively. The spleen was palpable in 76% of patients with a median of 9 cm (range, 1 to 32) below the costal margin. The median leukocyte count was 222 G/L (quartile 95-353). First-line therapy consisted of imatinib in 482 children. Among them, 40% remained on imatinib with a median follow-up 3.8 years (95% CI: 3.2-4.3 years); 3.1% died and 3.9% progressed to advanced phase disease. The overall survival rate at 36 months was 97.4% (95% CI: 95-99%). Progression free survival rate at 3-years was 97.1% (95% CI: 94.9-99.2%), 91.7% (95% CI:84.5-98.3%) and 72.0% (95% CI: 59-87.9%) in the Eutos Long Term Survival (ELTS) low, intermediate-, and high-risk group, respectively (p log rank.
Authors
- Joe De Keizer (ORCID: https://orcid.org/0000-0003-0821-4540)
- Krzysztof Kałwak (ORCID: https://orcid.org/0000-0003-1174-5799)
- Roula Farah (ORCID: https://orcid.org/0000-0002-6392-1590)
- Markus Metzler (ORCID: https://orcid.org/0000-0002-4523-1676)
- Meinolf Suttorp (ORCID: https://orcid.org/0000-0002-9522-8838)
- A. Honrubia
- Maaike Luesink
- Birgitte Lausen (ORCID: https://orcid.org/0000-0002-5306-0774)
- Michael Dworzak (ORCID: https://orcid.org/0000-0002-8175-1097)
- Μirella Αmpatzidou (ORCID: https://orcid.org/0000-0002-2480-7883)
- Barbara De Moerloose (ORCID: https://orcid.org/0000-0002-2449-539X)
- Marina Borisevich (ORCID: https://orcid.org/0000-0002-5180-5584)
- Julia Yajima (ORCID: https://orcid.org/0000-0001-7647-6222)
- Adalet Meral Güneş (ORCID: https://orcid.org/0000-0002-0686-7129)
- Alexandra Kolenová (ORCID: https://orcid.org/0000-0003-4300-5533)
- Frédéric Millot (ORCID: https://orcid.org/0000-0002-8912-4776)
- Chi Kong Li (ORCID: https://orcid.org/0000-0002-2810-5758)
- Gordana Jakovljević (ORCID: https://orcid.org/0000-0001-6670-4826)
- Petr Sedláček (ORCID: https://orcid.org/0000-0001-7895-2886)
- André Baruchel (ORCID: https://orcid.org/0000-0001-7445-1005)
- Lisa Durocher (ORCID: https://orcid.org/0009-0001-0547-7874)
Institutions
- Inserm (FR)
- Charles University (CZ)
- Hospital Universitario Insular de Gran Canaria (ES)
- University Medical Center Rizk Hospital (LB)
- Ghent University Hospital (BE)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Université de Poitiers (FR)
- Wroclaw Medical University (PL)
- Universitätsklinikum Erlangen (DE)
- University Hospital Bratislava (SK)
- University Hospital in Motol (CZ)
- Centro Infantil Boldrini (BR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Prince of Wales Hospital (CN)
- Association Robert Debré (FR)
- Children's Hospital Agia Sophia (GR)
- St Anna Children's Hospital (AT)
- Hôpital Robert-Debré (FR)
- Princess Máxima Center (NL)
- Children's Hospital Zagreb (HR)
- Belarusian Research Center For Pediatric Oncology and Hematology (BY)
- S.B.Ü. Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi (TR)
- Comenius University Bratislava (SK)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- Haematologica
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3324/haematol.2025.288283
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- University of Oxford
- Université de Poitiers
- Medical Research Council